Rapid Communication

Perinuclear anti-neutrophil cytoplasmic antibodies (p-ANCA) in chronic ulcerative colitis: Experience in a Mexican institution

Jesus K Yamamoto-Furusho, Takeshi Takahashi-Monroy, Omar Vergara-Fernandez, Edgardo Reyes, Luis Uscanga

AIM: To assess the prevalence and clinical value of p-ANCA in a sample of Mexican ulcerative colitis (UC) patients.

METHODS: In a prospective, IRB-approved protocol, p-ANCA was determined in 80 patients with UC (mean age, 32 ± 12.9 years). The severity and extension of disease were determined by clinical methods, searching a statistical association with p-ANCA status.

RESULTS: p-ANCA were detected in 41 (51%) patients. Severity of disease was the only clinical variable statistically associated with their presence (P < 0.0001; OR = 9; CI 95% = 3.2-24.7).

CONCLUSION: The prevalence of p-ANCA was similar to that reported in other countries. Their presence was associated to UC severity, but offered no more information than the obtained by clinical methods.

© 2006 The WJG Press. All rights reserved.

Key words: Ulcerative colitis; Inflammatory bowel disease; Perinuclear anti-neutrophil cytoplasmic antibodies

Abstract

INTRODUCTION

Anti-neutrophil cytoplasmic antibodies (ANCA) have been described in subjects with different types of vasculitis, and they are essential to establish the diagnosis of Wegener’s granulomatosis, microscopic polyangiitis, Churg-Strauss Syndrome and renal-limited vasculitises. Perinuclear anti-neutrophil cytoplasmic antibodies (p-ANCA), a subset of ANCA, have been described in patients with inflammatory bowel disease, mainly ulcerative colitis (UC). However, their role in pathogenesis and diagnostic value are still controversial. Previous reports have suggested that p-ANCA might be a sensitive and specific test to diagnose UC, to distinguish it from Crohn’s disease and other colitides, and to provide a prognosis regarding response to medical treatment and risk of pouchitis following the pelvic pouch.

The prevalence of p-ANCA in patients with UC varied from 40% to 88%. High titers have been reported by some authors in subjects with active disease, but its clinical value is controversial because others have not found any correlation between their levels and the activity or extension of disease.

The value of a diagnostic test, such as p-ANCA, should be evaluated by several practical factors like costs, availability, and usefulness for clinical decisions before accepting them as a standard diagnostic tool.

The aim of this study was to assess the prevalence and clinical usefulness of p-ANCA in a sample of Mexican patients with UC.

MATERIALS AND METHODS

A prospective study was performed at the Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, which is a referral center for gastrointestinal diseases in Mexico City. The protocol was reviewed and approved by the Institutional Review Board. All patients invited to participate in the study signed an informed consent before inclusion. Eighty consecutive patients with diagnosis of UC were included. In all cases, the diagnosis of UC was based on clinical, endoscopic and histopathologic findings. The extension of disease was determined by total colonoscopy...
copy, and categorized into pancolonic or left-sided colitis. The severity of disease was determined on clinical basis according to the Truelove and Witts criteria\[19\], and categorized into mild, moderate and severe. Clinical data, including severity and extension of disease were collected by an investigator who was blind to the results of p-ANCA.

**p-ANCA determination**

Detection of ANCA was done by Indirect Immunofluorescence (IFL), in accordance with the recommendation of the International Workshop\[20\]. Human neutrophils were prepared from peripheral blood of patients and normal healthy volunteers. The slides were fixed in 98% ethanol at 4°C for five minutes and dried quickly in air. After using phosphate-buffered saline (PBS) in a dilution of 1:40, the elements where dissolved twofold until it reached 1:320. Following incubation for 1 h at RT, the slides were washed three times with PBS and bound antibodies were incubated for 30 min and detected with FITC-conjugated rabbit anti-human IgG at RT. Subsequently, the slides were washed three times with PBS and covered with glycine-phosphate-buffered saline. A titer of 1:20 or higher was considered positive.

The antigen-specific enzyme-linked immunosorbent assay (ELISA) method was used to test the sera for the presence of either mieloperoxidase (MPO) or anti-proteinase-3 antibodies. Human MPO or human proteinase-3 were diluted to 2 mg/L in carbonate buffer (pH 9.6) and 100 μL of each solution was placed in the wells of a 96-well microplate and left for 24 h at 4°C. After plate was washed with PBS three times, 100 μL of diluted sera (1:100 in PBS containing 0.1% tween 20 and 0.1% skim milk) was added to each well, and the plate incubated for 1 h at 37°C. After washing, the enzyme reaction was performed, and color development was measured with a microplate colorimeter. Optical density values > 2 SD more than the mean of the control subjects were considered positive.

**Statistical analysis**

The student t -test was used for dimensional variables, and the association between categorical variables was studied by means of the χ² with Yates correction. The P values were 2-tailed and less than 0.05 was considered statistically significant.

**RESULTS**

Eighty patients with diagnosis of UC were included. There were 41 men and 39 women, with a mean age of 32 ± 12.9 years. The mean duration of disease was 7.2 ± 6.6 years. Pancolitis was present in 58% and left-sided colitis in 42%. Disease severity was categorized as severe in 20 (25%), moderate in 7 (10%), mild in 15 (18%), and there was no evidence of activity in the remaining 38 (47%) patients. Extraintestinal manifestations were present in 43%; and corresponded to arthritis (23%), primary sclerosing cholangitis (7.5%), erythema nodosum (5%), ankylosing spondylitis (2.5%), pyoderma gangrenosum (2.5%), anterior uveitis (2.5%), and aphthous ulcers (2.5%). Fourteen (25%) patients required surgical treatment due to failure of medical therapy.

The p-ANCA were detected by IFL in 41 (51%) and c-ANCA in 4 (5%) patients. Titers ranged from 1:20 to 1:160. The antigenic specificity of p-ANCA tested by ELISA in 33 patients showed a positive reaction for myeloperoxidase in 29 and proteinase-3 in 4. Age, gender and age at diagnosis was similar between patients with or without p-ANCA.

A statistical association was observed between p-ANCA status and the severity of UC (P = < 0.0001; OR 9, CI 3.2-24.7). Twenty-two (48%) patients with pancolitis and 19 (56%) with left-sided colitis were positive for p-ANCA (P = 0.47; OR = 0.72; 95% CI: 0.27-1.94). Seven out of the 14 (50%) patients who underwent surgical treatment were positive as compared with 34 of 66 (52%) who were not operated upon [P = 0.91; OR = 0.94; 95% CI: 0.26-3.34]. No association was found between the presence of extraintestinal manifestations and p-ANCA. See Table 1.

![Table 1 Clinical features in UC patients with positive and negative p-ANCA](www.wjgnet.com)

| Clinical feature | p-ANCA +  | p-ANCA -  | P value | OR  | CI 95% |
|------------------|----------|----------|--------|-----|------|
| Pancolitis       | 22       | 24       | 0.62   | 0.72| (0.29-1.76) |
| Left-sided       | 19       | 15       |        |     |      |
| Colectomy        | 7        | 7        | 0.84   | 0.94| (0.29-2.98) |
| No colectomy     | 34       | 32       |        |     |      |
| EIMs present     | 14       | 17       | 0.52   | 0.67| (0.27-1.65) |
| EIMs absent      | 27       | 22       |        |     |      |
| Severe           | 31       | 10       | < 0.0001| 9 | (3.2-24.7) |
| No Severe        | 10       | 29       |        |     |      |

**DISCUSSION**

The determination of p-ANCA could give information in subjects with UC in three different clinical issues: (1) as a marker of genetic heterogeneity; (2) to assess inflammatory activity, and (3) for prognosis regarding response to medical treatment and postoperative outcome (pouchitis).

The prevalence of p-ANCA in our series was 51%, within the range published by other authors in different parts of the world\[9,13\]. It supports that not all patients with UC exhibit the same immunologic pattern, a fact against a pathogenic role of ANCA’s in subjects with UC. On the other hand, the wide range of prevalence reported in the literature that goes from 40 to 88% could be rather explained by ethnic or genetic variations than by technical difficulties since both, IFL and ELISA, are simple, sensible, and reproducible assays, as observed in the present study\[14-23\].

Ethnic and genetic variability have been consistently reported in patients with IBD\[22,23\]. In a previous study, the authors found that Mexican patients with UC had an increased frequency of HLA-DR1 (DRB1*0102 and 0103) and HLA-DR2 (DRB1*15) when compared with healthy controls. HLA-DRB1*0103 and *0102 were associated
with more severe disease and necessity of surgical treatment [24]. Yang et al observed a linkage between p-ANCA positive UC patients and HLA-DR2[25]. The clinical usefulness of p-ANCA as a genetic marker was suggested many years ago by Shanahan who found a higher prevalence of p-ANCA in first-degree relatives of patients with UC[26]. This finding was confirmed by Llecu [27] et al, in a different ethnic group. So, p-ANCA determination could be useful as a marker of genetic predisposition. However, today there is no information about predictive values of p-ANCA in this setting, and more research is necessary to answer this important question.

Several studies, although not all, have demonstrated a correlation between serum levels of p-ANCA and severity of UC[12,13,19,21] In the present study, an association between the presence of p-ANCA and a subset of patients with severe UC was found but, as other studies, there was no correlation between levels of p-ANCA and the activity of disease evaluated by clinical and biochemical methods. From the point of view of the authors, a sophisticated laboratory exam such as the p-ANCA determination may not currently have a role in the evaluation of severity because it can be evaluated by simple and reproducible methods.

Fleshner et al, reported high pre-operative levels of p-ANCA in subjects who developed chronic pouchitis after the ileo-anal pouch[8]; however, it should be noted that some patients with acute and chronic pouchitis were p-ANCA negatives. The follow-up of patients in our series is still too short to analyze this aspect.

In conclusion, the prevalence of p-ANCA in this series was similar to that reported in other countries. Their presence was associated to severity of UC, but offered no more information than the obtained by clinical methods. Future research may clarify their role as a screening test for the first-degree relatives of UC patients, or for patients requiring an ileo-anal pouch.

REFERENCES

1. Hoffman GS, Specks U. Antineutrophil cytoplasmic antibodies. Arthritis Rheum 1998; 41: 1521-1537.
2. Guillevin L, Durand-Gasselin B, Cevallos R, Gayraud M, Lhote F, Callard P, Amouroux J, Casassus P, Jarrousse B. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 1999; 42: 421-430.
3. Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P. Churg-Strauss syndrome. Clinical study and long-term follow-up of 86 patients. Medicine (Baltimore) 1999; 78: 26-37.
4. Woodworth TG, Abuelo JG, Austin HA 3rd, Esparza A. Severe glomerulonephritis with late emergence of classic Wegener’s granulomatosis. Report of 4 cases and review of the literature. Medicine (Baltimore) 1987; 66: 181-191.
5. Cambridge G, Rampton DS, Stevens TR, McCarthy DA, Kamm M, Leaker B. Anti-neutrophil antibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 1992; 33: 668-674.
6. Shanahan F. Neutrophil autoantibodies in inflammatory bowel disease: are they important? Gastroenterology 1994; 107: 586-589.
7. Duerr RH, Targan SR, Landers CJ, Sutherland LR, Shanahan F. Anti-neutrophil cytoplasmic antibodies in ulcerative colitis. Comparison with other colitides/diarrheal illnesses. Gastroenterology 1991; 100: 1590-1596.
8. Fleshner PR, Vasilioukas EA, Kam LY, Fleshner NE, Gaennie J, Abreu-Martin MT, Targan SR. High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis. Gut 2001; 49: 671-677.
9. Lombardi G, Annese V, Piepoli A, Bovio P, Latiano A, Napolitano G, Perri F, Consortio P, Andriulli A. Antineutrophil cytoplasmic antibodies in inflammatory bowel disease: clinical role and review of the literature. Dis Colon Rectum 2000; 43: 999-1007.
10. Sugi K, Saitoh O, Matsuse T, Tabata K, Uchida K, Kojima K, Nakagawa K, Tanaka S, Teranishi T, Hirata J, Katsu K. Antineutrophil cytoplasmic antibodies in Japanese patients with inflammatory bowel disease: prevalence and recognition of putative antigens. Am J Gastroenterol 1999; 94: 1304-1312.
11. Kull K, Salupere R, Ilbo R, Ots M, Salupere V. Antineutrophil cytoplasmic antibodies in Estonian patients with inflammatory bowel disease. Prevalence and diagnostic role. Hepatogastroenterology 1998; 45: 2132-2137.
12. Abad E, Tural C, Mirapeix E, Cuxart A. Relationship between ANCA and clinical activity in inflammatory bowel disease: variation in prevalence of ANCA and evidence of heterogeneity. J Autimmun 1997; 10: 175-180.
13. Hertervig E, Wieslander J, Johansson C, Wiik A, Nilsson A. Anti-neutrophil cytoplasmic antibodies in chronic inflammatory bowel disease. Prevalence and diagnostic role. Scand J Gastroenterol 1999; 30: 693-698.
14. Saxon A, Shanahan F, Landers C, Ganz T, Targan S. A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J Allergy Clin Immunol 1990; 86: 202-210.
15. Rump JA, Schölmerich J, Gross V, Roth M, Hellesrieder R, Rautmann A, Lüdemann J, Gross WL, Peter HH. A new type of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) in active ulcerative colitis but not in Crohn’s disease. Immunobiology 1990; 181: 406-413.
16. Satsangi J, Landers CJ, Welsh KI, Koss K, Targan S, Jewell DP. The presence of anti-neutrophil antibodies reflects clinical and genetic heterogeneity within inflammatory bowel disease. Inflamm Bowel Dis 1998; 4: 18-26.
17. Rozendaal C, Pogány K, Hummel H, Horst G, Dijkstra G, Nielis GF, Limburg P, Mander JK, Kallenberg CG. Titres of anti-neutrophil cytoplasmic antibodies in inflammatory bowel disease are not related to disease activity. J Clin Immunol 1999; 30: 651-658.
18. Sandborn WJ, Landers CJ, Tremaine WJ, Targan SR. Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study. Mayo Clin Proc 1996; 71: 431-436.
19. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955; 2: 1041-1048.
20. Wiik A. Delineation of a standard procedure for indirect immunofluorescence detection of ANCA. APMIS Suppl 1989; 6: 12-13.
21. Sobajima J, Ozaki S, Osakada F, Uesugi H, Shirakawa H, Yoshida M, Nakao K. Novel autoantigens of perinuclear anti-neutrophil cytoplasmic antibodies (P-ANCA) in ulcerative colitis: non-histone chromosomal proteins, HMG1 and HMG2. Clin Exp Immunol 2001; 137: 135-140.
22. Asakura H, Sugimura K. HLA, antineutrophil cytoplasmic autoantibody, and heterogeneity in ulcerative colitis. Gastroenterology 1995; 108: 597-599.
23. Perri F, Annese V, Piepoli A, Napolitano G, Lombardi G, Cusarella G, Di Giorgio G, Andriulli A. HLA antigens and pANCA define ulcerative colitis as a genetically heterogeneous disorder. Ital J Gastroenterol Hepatol 1998; 30: 56-61.
24. Yamamoto-Furusho JK, Uscanga LF, Vargas-alarcon G, Ruiz-Moraes JA, Higuera L, Curiño T, Rodriguez-Pérez JM, Villarreal-Garza C, Granados J. Clinical and genetic heterogeneity in Mexican patients with ulcerative colitis. Hum Immunol 2003; 64: 119-123.
25. Yang H, Rotter JI, Toyoda H, Landers C, Tyran D, McElree CK, Targan SR. Ulcerative colitis: a genetically heterogeneous disorder defined by genetic (HLA class II) and subclinical
(antineutrophil cytoplasmic antibodies) markers. J Clin Invest 1993; 92: 1080-1084

26 Shanahan F, Duerr RH, Rotter JI, Yang H, Sutherland LR, McElree C, Landers CJ, Targan SR. Neutrophil autoantibodies in ulcerative colitis: familial aggregation and genetic heterogeneity. Gastroenterology 1992; 103: 456-461

27 Lee JC, Lennard-Jones JE, Cambridge G. Antineutrophil antibodies in familial inflammatory bowel disease. Gastroenterology 1995; 108: 428-433

28 Rump JA, Roth M, Schölmerich J, Helfesrieder R, Lüdemann J, Gross WL, Rautmann A, Peter HH. [A new type of ANCA in sera of patients with ulcerative colitis: effects of therapy and disease severity on serum titer]. Immun Infekt 1992; 20: 16-18

29 Broekroelofs J, Mulder AH, Nelis GF, Westerveld BD, Tervaert JW, Kallenberg CG. Anti-neutrophil cytoplasmic antibodies (ANCA) in sera from patients with inflammatory bowel disease (IBD). Relation to disease pattern and disease activity. Dig Dis Sci 1994; 39: 545-549

30 Seibold F, Weber P, Klein R, Berg PA, Wiedmann KH. Clinical significance of antibodies against neutrophils in patients with inflammatory bowel disease and primary sclerosing cholangitis. Gut 1992; 33: 657-662

31 Peen E, Almer S, Bodemar G, Rydén BO, Sjölin C, Tejle K, Skogh T. Anti-lactoferrin antibodies and other types of ANCA in ulcerative colitis, primary sclerosing cholangitis, and Crohn's disease. Gut 1993; 34: 56-62